Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 508 participants.
Also called NCT01788358
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 508 participants
- Sponsor
- Registry
-
NCT01788358 -
2012-004515-32
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Canada, Germany, Poland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01788358. Allocation not applicable; no masking; primary purpose treatment. Start 2013-02-14 (actual); primary completion 2014-05-01 (actual). Results posted on 2015-08-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Intervention (Drug)
- Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Intervention (Drug)
- Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Intervention (Drug)
- Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct01788358- Content hash
c74a615e4a99203a520eb7161962e431b363fe4be907b429fbdedb328871e829